|   | 
                  
                       | 
                      | 
                    
                        
                            
                                | 
                                  
                                 | 
                             
                             |  
                            
                                
                                    
                                        
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    ¿ÀºÎÄÚÆ®½ºÀ®Çï·¯(¹ÌºÐȺε¥¼Ò´Ïµå) 200ȸ  OBUCORT SWINGHALER 40mg  
                    
                 | 
               
              
                | 
                     Àü¹®ÀǾàǰ | »èÁ¦  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |                   
                                        | 
                                             | 
                                         
                            
                                
                            
                            
                              
                                                        
                              
                                                
                            
 |   
    | 
      
     | 
 
 |  
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
  
  
    
      
  
    
       |  
      
        
          
            
                | Çã°¡Á¤º¸ | 
             
           
         | 
       
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
  
  
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        649900160[A42750112]  
	    
	    
            [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \0 ¿ø/200ȸ/1Åë(2016.10.01)(ÇöÀç¾à°¡)
            \18,696 ¿ø/200ȸ/1Åë(2014.02.01)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
      [Áúº´ÄÚµåÁ¶È¸]
     
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
  
   
    | Á¦Ç°¼º»ó | 
    ÇÃ¶ó½ºÆ½ ÈíÀԱ⿡ ¹é»ö ºÐ¸»ÀÌ ÃæÁøµÈ ÈíÀÔÁ¦  [Á¦ÇüÁ¤º¸ È®ÀÎ] |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    200ȸ/Åë | 
   
  
  
  
   
    | Æ÷À塤ÄÚµå´ÜÀ§ | 
    
        
        
            | ¾àǰ±Ô°Ý | 
            ´ÜÀ§ | 
            Æ÷ÀåÇüÅ | 
            ´ëÇ¥ÄÚµå | 
            Ç¥ÁØÄÚµå | 
            ºñ°í | 
	     
        
        
            | 40¹Ð¸®±×·¥ | 
            1 Åë | 
            Åë | 
            8806499001601 | 
            8806499001618 | 
            200dose | 
	     
        
         
     | 
   
      
  
  	
   
    | ÁÖ¼ººÐÄÚµå | 
    
      119505CSI  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
     | 
   
  
  
  
 
  
  
    
  
  
  
  
  
  
  
  
  
  
 
  
  
  
 
  
  
  
  
  
  
   
    | Çã°¡»çÇ× ¿ø¹®Á¶È¸ | 
    
      
	    [Çã°¡»çÇ× ¿ø¹®Á¶È¸] 
     | 
   
  
  
  
  
     
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      ±â°üÁöõ½Ä 
      
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
  
  
  
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
      [󹿾à¾î] 
      ½ÉÇÑ Ãµ½Ä±â°£ÀÇ Ä¡·á¿ä¹ýÀ¸·Î¼ ÄÚÆ¼ÄÚ½ºÅ×·ÎÀ̵åÀÇ ÈíÀÔ Åõ¿©¸¦ ½ÃÀÛÇÒ ¶§ ±×¸®°í °æ±¸ ½ºÅ×·ÎÀ̵带 °¨·®Çϰųª Áß´ÜÇϰíÀÚ ÇÒ ¶§ÀÇ ¿ë¹ýÀº ´ÙÀ½°ú °°½À´Ï´Ù.  
1. ¼ºÀÎ(12¼¼ÀÌ»ó) 
: 1ÀÏ 200 ¢¦ 1600 §¶ÀÇ ¿ë·®À» 2 ¢¦ 4ȸ ºÐÇÒ Åõ¿©ÇÕ´Ï´Ù. 
°æÁõ 1ÀÏ 200 ¢¦ 800 §¶, ÁßÁõ 1ÀÏ 800 ¢¦1600 §¶ 
´Ü, À¯Áö¿ë·®ÀÌ 1ÀÏ 800 §¶ÀÎ °æ¿ì 1ÀÏ 1ȸ Åõ¿©µµ °¡´ÉÇÕ´Ï´Ù.  
2. ¼Ò¾Æ(5 ¢¦ 12¼¼ ÀÌÇÏ) 
: 1ÀÏ 200 ¢¦ 800 §¶ÀÇ ¿ë·®À» 2 ¢¦ 4ȸ ºÐÇÒ Åõ¿©ÇÕ´Ï´Ù. 
ÁßÁõ õ½ÄÀÇ °æ¿ì 1ÀÏ Åõ¿©·®Àº 800 §¶±îÁö Áõ·®ÇÒ ¼ö ÀÖ½À´Ï´Ù. 
´Ü, À¯Áö¿ë·®ÀÌ 1ÀÏ 400 §¶ÀÎ °æ¿ì 1ÀÏ 1ȸ Åõ¿©µµ °¡´ÉÇÕ´Ï´Ù  
Ä¡·áÈ¿°ú¸¦ ÁõÁø½Ã۰íÀÚ Çϴ ȯÀÚ¿¡°Ô´Â °æ±¸ ÄÚÆ¼ÄÚ½ºÅ×·ÎÀ̵åÁ¦¿ÍÀÇ º´¿ë¿ä¹ýº¸´Ù´Â ÀϹÝÀûÀ¸·Î º»Á¦ÀÇ ¿ë·®À» Áõ°¡½ÃŰ´Â °ÍÀÌ Àü½ÅÀû ºÎÀÛ¿ëÀÇ À§ÇèÀÌ ÀûÀ¸¹Ç·Î ´õ¿í ¹Ù¶÷Á÷ÇÕ´Ï´Ù.  
°æ±¸½ºÅ×·ÎÀ̵忡 ºñÀÇÁ¸ÀûÀΠȯÀÚ 
: Ä¡·áÈ¿°ú´Â Åë»ó 10ÀÏ À̳»¿¡ ³ªÅ¸³³´Ï´Ù. ±â°üÁö¿¡ °úÀ×ÀÇ Á¡¾×ºÐºñ°¡ Àִ ȯÀÚ¿¡°Ô´Â Ãʱ⿡ °æ±¸ ½ºÅ×·ÎÀ̵åÁ¦¿Í ÇÔ²² ´Ü±â°£ Åõ¿©ÇÒ ¼öµµ ÀÖ½À´Ï´Ù.  
°æ±¸ ½ºÅ×·ÎÀ̵忡 ÀÇÁ¸¼ºÀΠȯÀÚ 
: °æ±¸ ½ºÅ×·ÎÀ̵åÁ¦¿¡¼ ¿ÀºÎÄÚÆ® ½ºÀ®Çï·¯·Î ÀüȯÇϰíÀÚ ÇÒ ¶§¿¡´Â ȯÀÚ´Â ºñ±³Àû ¾ÈÁ¤µÈ »óÅ¿©¾ß ÇÕ´Ï´Ù. °í¿ë·®ÀÇ ¿ÀºÎÄÚÆ® ½ºÀ®Çï·¯¸¦ ¾à 10ÀÏ ÀÌ»ó ÀÌÀü¿¡ »ç¿ëÇÑ °æ±¸½ºÅ×·ÎÀ̵å¿Í º´¿ëÇÏ¿© Åõ¿©ÇÕ´Ï´Ù.  
ÀÌÈÄ·Î °æ±¸¿ë·®Àº °¡´ÉÇÑ ÇÑ ÃÖ¼Ò·®¿¡ À̸¦ ¶§±îÁö, ¿¹ÄÁ´ë prednisolonÀÇ °æ¿ì ¸Å¿ù 2.5 mg¾¿ ¶Ç´Â ÀÌ¿Í µ¿µîÇÑ ¾çÀ¸·Î Á¡Â÷ °¨¼Ò½Ãŵ´Ï´Ù.  
°æ±¸ ½ºÅ×·ÎÀ̵åÁ¦¸¦ ¿ÀºÎÄÚÆ® ½ºÀ®Çï·¯·Î ¿ÏÀüÈ÷ ´ëüÇÒ ¼ö ÀÖ½À´Ï´Ù.      
      	
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    ºÎµ¥¼Ò´Ïµå¿¡ °ú¹ÎÁõÀΠȯÀÚ  | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    Æó°áÇ٠ȯÀÚ, Áø±Õ ¹× ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ ±âµµ °¨¿° ȯÀÚÀÇ °æ¿ì °¢º°È÷ ÁÖÀǰ¡ ÇÊ¿äÇÕ´Ï ´Ù.  | 
   
  
    
  
  
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
       1) ÀÎÈÄÀÇ °æ¹ÌÇÑ Àڱرâħ ¸ñÀÌ ½¬´Â °æ¿ì°¡ º¸°íµÈ ¹Ù ÀÖ½À´Ï´Ù. 
2) ±¸°Àεο¡ ĵð´Ù °¨¿°ÁõÀÌ ¶§¶§·Î º¸°íµÈ ¹Ù ÀÖ½À´Ï´Ù. 
3) ºñƯÀÌÀû ¹ÝÀÀÀ¸·Î µå¹°°Ô ±â°üÁö °æ·ÃÀ» ÀÏÀ¸Å³ ¼ö ÀÖÁö¸¸ ÇöÀç±îÁö º»Á¦ÀÇ »ç¿ëÀ¸ ·Î ³ªÅ¸³ °æ¿ì´Â ¾ø½À´Ï´Ù. 
4) ÈçÇÏÁö ¾Ê°Ô ½Ã¾ßÈ帲ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
      
     | 
   
        
  
  
  
    
  
  
       	
  
     
  
  
  
  
  
  
  |  
     
   
  
    
       |  
      
        
          
            
                | Á¤º¸¿ä¾à |         
             
           
         | 
             	    
       |  
      | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
     
   
  
    
       |  
      
        
          
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |         
             
           
         | 
             	    
       |  
      | 	 |  
     
   
  
    
       |  
      
        
          
            
                | Á¦Ç°Á¤º¸ |            
             
           
         | 
             	  
       |  
       |  
     
   
  
    
       |  
      
        
          
            
                | º¹¾àÁ¤º¸ |            
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
  
   
    | Ãà¾àº¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Bµî±Þ 
				        	
					  
					
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
  
  
  
  
  
  
   
    | º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ | 
    
      [º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
     | 
   
  	
  
  
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
     
   
  
    
       |  
      
        
          
            
                | ½É»çÁ¤º¸ |            
             
           
         | 
             	  
       |  
       |  
     
     
  
    
       |  
      
        
          
            
                | ÇмúÁ¤º¸ |          
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | Mechanism of Action | 
    
       Budesonide¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The exact mechanism of action of budesonide in the treatment of Crohn's disease is not fully understood. However, being a glucocorticosteroid, budesonide has a high local anti-inflammatory effect. 
     | 
   
  
   
    | Pharmacology | 
     
       Budesonide¿¡ ´ëÇÑ Pharmacology Á¤º¸ Budesonide is a synthetic corticosteroid used in Crohn's disease to decrease the symptoms and inflammation associated with the disease, especially at times of flare up. Budesonide has a high topical glucocorticosteroid (GCS) activity and a substantial first pass elimination. The formulation contains granules which are coated to protect dissolution in gastric juice, but which dissolve at pH >5.5, ie, normally when the granules reach the duodenum. Thereafter, a matrix of ethylcellulose with budesonide controls the release of the drug into the intestinal lumen in a time-dependent manner. 
     | 
   
  
   
    | Metabolism | 
    
       Budesonide¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4) 
     | 
   
  
   
    | Absorption | 
    
       Budesonide¿¡ ´ëÇÑ Absorption Á¤º¸ Absorption is complete following oral administration. 
     | 
   
  
   
    | Toxicity | 
    
       Budesonide¿¡ ´ëÇÑ Toxicity Á¤º¸ Single oral doses of 200 and 400 mg/kg were lethal in female and male mice, respectively. The signs of acute toxicity were decreased motor activity, piloerection and generalized edema. 
     | 
   
  
   
    | Drug Interactions | 
    
       Budesonide¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Itraconazole	The imidazole increases levels/effect of budesonideKetoconazole	The imidazole increases levels/effect of budesonide 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Food Interaction | 
    
       Budesonide¿¡ ´ëÇÑ Food Interaction Á¤º¸ A mean delay in time to peak concentration of 2.5 hours is observed with the intake of a high-fat meal, with no significant differences in AUC. 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | SNP Á¤º¸ | 
    
      Name:Budesonide (DB01222)
 Interacting Gene/Enzyme:T-box transcription factor TBX21 (Gene symbol = TBX21) Swissprot Q9UL17
 SNP(s):rs2240017 (C Allele)
 Effect:Improved response for long-term asthma treatment
 Reference(s):Tantisira KG, Hwang ES, Raby BA, Silverman ES, Lake SL, Richter BG, Peng SL, Drazen JM, Glimcher LH, Weiss ST: TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18099-104. Epub 2004 Dec 16. [PubMed] 
     | 
   
  
   
    | Description | 
    
       Budesonide¿¡ ´ëÇÑ Description Á¤º¸ A glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis. [PubChem] 
     | 
   
  
   
    | Dosage Form | 
    
       Budesonide¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Aerosol, metered	NasalAerosol, metered	Respiratory (inhalation)Capsule, extended release	OralSuspension	NasalSuspension	Respiratory (inhalation) 
     | 
   
  
   
    | Drug Category | 
    
       Budesonide¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-inflammatory AgentsBronchodilator AgentsCorticosteroidsGlucocorticoids 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Budesonide¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(O1)C(=O)CO 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Budesonide¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO 
     | 
   
  
   
    | InChI Identifier | 
    
       Budesonide¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21-,22+,23-,24-,25+/m0/s1 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Budesonide¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ Not Available 
     | 
   
    
  |  
     
     
  
    
       |  
      
        
          
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ |           
             
           
         | 
             	  
       |  
       |  
     
         
 
     | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-12-05
              
 
              - 
                
                 º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
  
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  [ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â]       Á¦¸ñ ¾øÀ½ 
 
    
    2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
    
    1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ  º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
    ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
          
    
    
    
    2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
    ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
 
 
 
   
  |  
                           
                         | 
                       
                      | 
                   |